Globule-size distribution in injectable 20% lipid emulsions: Compliance with USP requirements

American Journal of Health-System Pharmacy

Volumn 64, Issue 19, 2007, Pages 2032-2036

  Driscoll, David F ^a,b  

^a Sterile Product Compounding Unit   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Control, quality; Fat emulsions; Glass; Packaging; Particle size distribution; Plastics; Standards; United States Pharmacopeia

Indexed keywords

CLINOLEIC; FAT DROPLET; INTRALIPID; LIPID EMULSION; LIPOSYN; LIPOSYN III; MEDIUM CHAIN TRIACYLGLYCEROL; NUTRIFLEX PERI; NUTRIFLEX SPECIAL; SOYBEAN PROTEIN; STRUCTOKABIVEN 1100; STRUCTOKABIVEN PERI; UNCLASSIFIED DRUG;

ARTICLE; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PACKAGING; DRUG QUALITY; GLOBULE SIZE DISTRIBUTION; INJECTION; LIGHT SCATTERING; PARTICLE SIZE; PRIORITY JOURNAL; QUALITY CONTROL;

EID: 34948872633     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070097     Document Type: Article

References (13)

1. Chapter 〈729〉: globule size distribution in lipid injectable emulsions. In: The United States pharmacopeia, 30th rev., and The national formulary, 25th ed., suppl. 2. Rockville, MD: United States Pharmacopeial Convention; 2007:3968-70.
2. Lipid injectable emulsion monograph. Pharm Forum. 2006; 32:350-3.
3. Baxter Healthcare Corporation. Announcement to directors of pharmacy: Intralipid i.v. fat emulsion now available in plastic containers. Deerfield, IL: 2004 Feb 26.
4. Driscoll DF, Etzler F, Barber TA et al. Physicochemical assessments of parenteral lipid emulsions: light obscuration versus laser diffraction. Int J Pharm. 2001;219:21-37.
5. Driscoll DF, Bistrian BR. The effects of packaging containers on the large-diameter tail of the globule size distribution (GSD) of lipid emulsions. Clin Nutr. 2005; 24:699. Abstract.
6. Driscoll DF, Thoma A, Klütsch K et al. The effects of packaging containers and manufacturer on the large-diameter tail of the globule size distribution of lipid injectable emulsions - part 2. Clin Nutr. 2005; 24:1126-7. Abstract.
7. Driscoll DF. Examination of selection of light-scattering and light-obscuration acceptance criteria for lipid injectable emulsions. Pharm Forum. 2004; 30:2244-53.
8. Driscoll DF, Silvestri AP, Bistrian BR et al. Stability of total nutrient admixtures with lipid injectable emulsions in glass vs. plastic packaging. Am J Health-Syst. 2007; 64:396-403.
9. Driscoll DF. Lipid injectable emulsions: pharmacopeial and safety issues. Pharm Res. 2006; 23:1959-69.
10. Driscoll DF, Bhargava HN, Li L et al. The physicochemical stability of complex intravenous lipid dispersions as total nutrient admixtures. Am J Health-Syst Pharm. 1995; 52:623-34.
11. Driscoll DF, Ling PR, Bistrian BR. Physical stability of 20% lipid injectable emulsions via simulated syringe infusion: effects of glass vs. plastic product packaging. J Parenter Enteral Nutr. 2007;31:148-53. [Erratum, J Parenter Enteral Nutr. 2007; 31:261.]
12. Martin CR, Dumas GJ, Shoaie C et al. Incidence of hypertriglyceridemia in critically ill neonates receiving lipid injectable emulsions in glass vs. plastic containers: a retrospective analysis. J Pediatr. In press.
13. Toce SS, Keenan WJ. Lipid intolerance in newborns is associated with hepatic dysfunction but not infection. Arch Ped Adolesc Med. 1995; 149:1249-53.